Kiyatec
Greenville, US · Founded 2010 · Delaware corporation · 14 employees on LinkedIn · 2 known investors
KIYATEC develops 3D Predict, a tumor-specific testing platform that uses patient-derived tumor cells to predict how individual cancers respond to therapies. It serves oncologists and cancer patients in the precision oncology and diagnostics space.
Founders & leadership
Kiyatec was founded in 2010 by Matthew Gevaert.
MG
Matthew GevaertFounder
EP
Eric PerreaultinExecutive
MR
Melissa RaynerExecutive
SI
Scott IsacksenExecutive
BS
Bob SilvermanNamed on SEC filing
HL
H. Lee Higdon IIINamed on SEC filing
DE
David E OrrChief Operating Officer
Board
CB
Christopher BrothertonBoard director
JR
RS
Robert SilvermanBoard director
BN
Bruce NashBoard director
ME
Martin EttlemyerBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$27M disclosed across 5 of 7 rounds · 2014–2024
▶$250KraisedNov 2024 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedNov 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric PerreaultExecutive Officer, Director
- Christopher BrothertonDirector
- Matthew GevaertDirector
- Melissa RaynerExecutive Officer
- Scott IsacksenExecutive Officer
- Jason RobartDirector
- Robert SilvermanDirector
- Bruce NashDirector
- Offering amount
- $5.4M
- Amount sold
- $250K
- Minimum investment
- $50K
- Sales commissions
- $206.5K
- Proceeds to insiders
- $830K
- Placement agents
- Nicholas McFarland
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.1MraisedDec 2022 · 23 investors · BiotechnologyRule 506(b)
▶$18.1MraisedDec 2022 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew R. GevaertExecutive Officer, Director
- Bruce NashDirector
- Jason RobartDirector
- Robert SilvermanDirector
- Christopher BrothertonDirector
- Offering amount
- $24.6M
- Amount sold
- $18.1M
- Sales commissions
- $611K
- Placement agents
- WILLIAM BLAIR & COMPANY L.L.C.
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.3MraisedMar 2019 · 15 investors · BiotechnologyRule 506(b)
▶$5.3MraisedMar 2019 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christine Dixon ThiesingDirector
- Gregory ZaicDirector
- Christopher BrothertonDirector
- Matthew R. GevaertExecutive Officer, Director
- Offering amount
- $14.3M
- Amount sold
- $5.3M
- Minimum investment
- $6.3K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MofferedNov 2017 · BiotechnologyRule 506(b)
▶$2MofferedNov 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert J. SilvermanDirector
- Christine Dixon ThiesingDirector
- Matthew R. GevaertExecutive Officer, Director
- Christopher BrothertonDirector
- Gregory ZaicDirector
- Offering amount
- $2M
- Proceeds to insiders
- $45K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.1MraisedOct 2016 · 24 investors · BiotechnologyRule 506(b)
▶$3.1MraisedOct 2016 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew GevaertExecutive Officer, Director
- Christopher BrothertonDirector
- Martin EttlemyerDirector
- Gregory ZaicDirector
- Bob SilvermanDirector
- Offering amount
- $5.2M
- Amount sold
- $3.1M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$180KraisedDec 2014 · 3 investors · BiotechnologyRule 506(b)
▶$180KraisedDec 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory ZaicDirector
- David E OrrExecutive Officer
- Bob SilvermanDirector
- Matthew GevaertExecutive Officer, Director
- H. Lee Higdon IIIDirector
- Christopher BrothertonDirector
- Offering amount
- $500K
- Amount sold
- $180K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500.5KofferedApr 2014 · BiotechnologyRule 506(b)
▶$500.5KofferedApr 2014 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory ZaicDirector
- Bob SilvermanDirector
- Christopher BrothertonDirector
- Matthew GevaertExecutive Officer, Director
- H. Lee Higdon IIIDirector
- David E OrrExecutive Officer
- Offering amount
- $500.5K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapDialectic Therapeutics10 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Newswise8 shared keywordsNewswise is a news distribution service that hosts and syndicates research news and press releases from universities, medical centers, and scientific organizations. It serves journalists and public information officers by aggregating expert content across fields such as science, medicine, and higher education.
Companies competing with Kiyatec for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $254.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $294.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Kiyatec do?
- KIYATEC develops 3D Predict, a tumor-specific testing platform that uses patient-derived tumor cells to predict how individual cancers respond to therapies. It serves oncologists and cancer patients in the precision oncology and diagnostics space.
- Who founded Kiyatec?
- Kiyatec was founded by Matthew Gevaert in 2010.
- Who are Kiyatec's investors?
- Kiyatec's investors include Atlanta Technology Angels, Seae Ventures.
- How much funding has Kiyatec raised?
- Kiyatec has disclosed $27M raised across 5 of its 7 known rounds.
- Where is Kiyatec headquartered?
- Kiyatec is headquartered in Greenville, US.